Market Closed -
NSE India S.E.
12:43:52 15/05/2024 BST
|
5-day change
|
1st Jan Change
|
2,191
INR
|
-2.58%
|
|
-1.20%
|
+10.50%
|
Fiscal Period: März |
2024
|
2025
|
2026
|
---|
Capitalization
1 |
877,589
|
-
|
-
|
Enterprise Value (EV)
1 |
852,336
|
834,169
|
814,137
|
P/E ratio
|
47.9
x
|
40.2
x
|
33.5
x
|
Yield
|
0.31%
|
0.44%
|
0.59%
|
Capitalization / Revenue
|
8.51
x
|
7.52
x
|
6.64
x
|
EV / Revenue
|
8.27
x
|
7.15
x
|
6.16
x
|
EV / EBITDA
|
34.2
x
|
28.3
x
|
23.5
x
|
EV / FCF
|
57.3
x
|
46.5
x
|
37
x
|
FCF Yield
|
1.75%
|
2.15%
|
2.7%
|
Price to Book
|
9.49
x
|
7.71
x
|
6.4
x
|
Nbr of stocks (in thousands)
|
400,588
|
-
|
-
|
Reference price
2 |
2,191
|
2,191
|
2,191
|
Announcement Date
|
-
|
-
|
-
|
Fiscal Period: März |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
87,494
|
103,113
|
116,643
|
132,256
|
EBITDA
1 |
-
|
19,006
|
24,937
|
29,450
|
34,602
|
EBIT
1 |
-
|
15,747
|
21,049
|
25,399
|
30,200
|
Operating Margin
|
-
|
18%
|
20.41%
|
21.78%
|
22.83%
|
Earnings before Tax (EBT)
1 |
-
|
16,712
|
23,287
|
27,785
|
33,247
|
Net income
1 |
14,335
|
12,819
|
18,298
|
21,751
|
26,165
|
Net margin
|
-
|
14.65%
|
17.75%
|
18.65%
|
19.78%
|
EPS
2 |
35.78
|
32.00
|
45.72
|
54.45
|
65.32
|
Free Cash Flow
1 |
-
|
10,243
|
14,885
|
17,942
|
21,979
|
FCF margin
|
-
|
11.71%
|
14.44%
|
15.38%
|
16.62%
|
FCF Conversion (EBITDA)
|
-
|
53.89%
|
59.69%
|
60.92%
|
63.52%
|
FCF Conversion (Net income)
|
-
|
79.91%
|
81.35%
|
82.49%
|
84%
|
Dividend per Share
2 |
-
|
-
|
6.850
|
9.683
|
12.82
|
Announcement Date
|
01/08/22
|
30/05/23
|
-
|
-
|
-
|
Fiscal Period: März |
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
25,786
|
26,998
|
24,214
|
24,228
|
EBITDA
1 |
6,548
|
6,987
|
5,822
|
5,585
|
EBIT
1 |
5,675
|
5,706
|
4,347
|
4,155
|
Operating Margin
|
22.01%
|
21.13%
|
17.95%
|
17.15%
|
Earnings before Tax (EBT)
1 |
6,245
|
6,229
|
4,984
|
4,776
|
Net income
1 |
4,869
|
5,176
|
4,194
|
3,823
|
Net margin
|
18.88%
|
19.17%
|
17.32%
|
15.78%
|
EPS
2 |
12.14
|
11.00
|
9.867
|
9.350
|
Dividend per Share
|
-
|
-
|
-
|
-
|
Announcement Date
|
02/08/23
|
-
|
-
|
-
|
Fiscal Period: März |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
25,253
|
43,420
|
63,452
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
10,243
|
14,885
|
17,942
|
21,979
|
ROE (net income / shareholders' equity)
|
-
|
18.9%
|
21.3%
|
21.1%
|
20.9%
|
ROA (Net income/ Total Assets)
|
-
|
13.6%
|
17.4%
|
18.3%
|
18.2%
|
Assets
1 |
-
|
94,317
|
105,403
|
118,963
|
143,389
|
Book Value Per Share
2 |
-
|
186.0
|
231.0
|
284.0
|
342.0
|
Cash Flow per Share
2 |
-
|
45.30
|
54.90
|
64.50
|
75.60
|
Capex
1 |
-
|
7,890
|
4,882
|
5,187
|
5,349
|
Capex / Sales
|
-
|
9.02%
|
4.73%
|
4.45%
|
4.04%
|
Announcement Date
|
01/08/22
|
30/05/23
|
-
|
-
|
-
|
Last Close Price
2,191
INR Average target price
2,186
INR Spread / Average Target -0.20% Consensus |
1st Jan change
|
Capi.
|
---|
| +10.50% | 10.79B | | +31.37% | 588B | | -2.74% | 364B | | +20.68% | 326B | | +5.68% | 285B | | +14.83% | 239B | | +9.93% | 210B | | -6.95% | 200B | | +11.25% | 167B | | -0.02% | 161B |
Other Pharmaceuticals
|